Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Status:
Recruiting
Trial end date:
2031-02-22
Target enrollment:
Participant gender:
Summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma
participants who continue to derive clinical benefit from elranatamab monotherapy in the
Pfizer-sponsored elranatamab Parent Studies.